RGNX - Regenxbio Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
32.75
+0.30 (+0.92%)
At close: 4:00PM EDT

32.75 0.00 (0.00%)
After hours: 5:08PM EDT

Stock chart is not supported by your current browser
Previous Close32.45
Open32.65
Bid31.75 x 100
Ask34.55 x 100
Day's Range32.00 - 33.05
52 Week Range15.40 - 36.10
Volume220,619
Avg. Volume315,596
Market Cap1.01B
BetaN/A
PE Ratio (TTM)-12.17
EPS (TTM)-2.69
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.25
Trade prices are not sourced from all markets
  • Capital Cube8 hours ago

    ETFs with exposure to REGENXBIO, Inc. : October 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to REGENXBIO, Inc. Here are 5 ETFs with the largest exposure to RGNX-US. Comparing the performance and risk of REGENXBIO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Barrons.com7 days ago

    Gene Therapies: A Foot in the Door

    The yes vote by the FDA advisory panel for Spark Therapeutics’ (ONCE) drug Luxturna has opened the door for gene therapies at the FDA. Leerink’s Joseph Schwartz weighed in on that very topic today. Proclaiming it “a new era for gene therapy,” he says the results of yesterday’s vote is a “momentous advance” for the drug category that suggests that the public’s and regulators’ long-standing caution is “at an inflection point.” If the FDA follows-through on today's unanimous vote and approves Luxturna by Jan 12, 2018, we believe the tailwind could benefit companies like Audentes (BOLD [OP]), BioMarin (BMRN [OP]), REGENXBIO (RGNX [NR]), uniQure (QURE [OP]) and Ultragenyx (RARE [OP]) post-DMTX acquisition.

  • Capital Cube11 days ago

    ETFs with exposure to REGENXBIO, Inc. : October 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to REGENXBIO, Inc. Here are 5 ETFs with the largest exposure to RGNX-US. Comparing the performance and risk of REGENXBIO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube14 days ago

    REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis REGENXBIO, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 6.56 million, Net Earnings of USD -14.47 million. Gross margins widened from 79.03% to 79.93% compared to the same period last year, operating (EBITDA) margins now -218.73% from -628.04%. Change in operating cash ... Read more (Read more...)

  • American City Business Journals17 days ago

    ​After bidding war, North Bay drug maker snags gene therapy company for $151 million

    After weighing buyout offers from two biotechs, gene therapy company Dimension Therapeutics said Tuesday that it accepted the superior proposal — a $151 million deal from a North Bay company that will allow the company to maintain a New England presence. Novato-based Ultragenyx Pharmaceutical (RARE) will buy Dimension (DMTX) for $6 per share. "I am thankful for the hard work and dedication of our talented employees, and am confident they will continue to make valuable contributions as part of a larger organization," Dimension CEO Annalisa Jenkins said in a statement.

  • American City Business Journals17 days ago

    ​After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout

    After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Dimension (DMTX) said it had agreed to be acquired by California-based Ultragenyx Pharmaceutical (RARE) for $6 per share.

  • TheStreet.com17 days ago

    Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

    Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

  • GlobeNewswire17 days ago

    Ultragenyx to Acquire Dimension Therapeutics

    Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares. Combined Company ...

  • GlobeNewswire17 days ago

    REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Oct. 03, 2017-- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology ...

  • American City Business Journals18 days ago

    RegenxBio declines to push forward on planned acquisition

    Rockville-based RegenxBio Inc. has opted to back away from a deal to buy Dimension Therapeutics Inc. (DMTX) after the Boston-area biotech received a better buyout offer. RegenxBio (RGNX) said Monday morning it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical (RARE), based in Novato, California, is now offering to Dimension Therapeutics, a Cambridge, Massachusetts, biotech that's struggled with its pipeline in the last year. In August, RegenxBio announced plans to buy Dimension in an all-stock transaction that valued the deal at $3.41 per share, or $86 million in all.

  • GlobeNewswire18 days ago

    REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics

    ROCKVILLE, Md., Oct. 02, 2017-- REGENXBIO Inc. today announced that Dimension Therapeutics, Inc. notified REGENXBIO that it has determined that it has received a“ superior proposal” as defined in the merger ...

  • GlobeNewswire18 days ago

    Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”

    CAMBRIDGE, Mass., Oct. 02, 2017-- Dimension Therapeutics, Inc. announced today that the Dimension Board of Directors has determined that an unsolicited proposal received from Ultragenyx Pharmaceutical ...

  • Investopedia21 days ago

    8 Stocks for the Next Gene Revolution

    The FDA may approve replacement gene therapy for the first time, giving a big boost to biotech firms.

  • Thomson Reuters StreetEvents22 days ago

    Edited Transcript of RGNX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Regenxbio Inc Earnings Call

  • Barrons.com25 days ago

    Gene Therapy: A Big Week for Many Names

    It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.

  • Barrons.com26 days ago

    [$$] Gene Therapy Is Nearing a Major Breakthrough

    After decades of research and development, gene therapy is rapidly emerging as one of the most exciting areas in biotechnology—and generating new hope for patients with certain rare and often deadly inherited diseases. Replacement gene therapy that uses neutered viruses to deliver healthy genes to the body is particularly promising, given its potential to cure a range of disorders with the administration of a single treatment. The first regulatory approval for this technology could come as soon as January, if the Food and Drug Administration gives the go-ahead to Spark Therapeutics (ONCE) for its one-time treatment that targets a rare, inherited retinal condition leading to blindness.

  • GlobeNewswirelast month

    REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

    Six patients dosed at leading retinal surgery centers in the United States All participating study centers now active; next dose cohort is projected to start after review by the Data Safety Monitoring ...

  • GlobeNewswirelast month

    Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”

    CAMBRIDGE, Mass., Sept. 19, 2017-- Dimension Therapeutics, Inc., a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated ...

  • GlobeNewswirelast month

    Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx

    CAMBRIDGE, Mass., Sept. 18, 2017-- Dimension Therapeutics, Inc., a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated ...

  • MarketWatchlast month

    UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid

    Dimension Therapeutics Inc. shares surged 38% in early afternoon trade Monday on news that Ultragenyx Pharmaceutical Inc. has proposed to buy all its outstanding common stock for $5.50 per share, or about ...

  • TheStreet.comlast month

    Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

    Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.

  • Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher
    Zackslast month

    Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher

    Regenxbio (RGNX) was a big mover last session, as the company saw its shares rise more than 9% on the day.

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTX

    NEW YORK , Aug. 31, 2017 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • GlobeNewswire2 months ago

    REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 31, 2017-- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology ...

  • DIMENSION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dimension Therapeutics, Inc.
    PR Newswire2 months ago

    DIMENSION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dimension Therapeutics, Inc.

    NEW ORLEANS , Aug. 28, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...